NASDAQ:LPCNLipocine Stock Price, Forecast & News

$0.90

0.00 (0.00 %)

(As of 06/5/2020 04:00 PM ET)

Add

Compare

Today's Range

$0.88

Now: $0.90▼

$0.92

50-Day Range

$0.48

MA: $0.72▼

$0.99

52-Week Range

$0.30

Now: $0.90▼

$3.45

Volume1.79 million shs

Average Volume1.41 million shs

Market Capitalization$43.09 million

P/E RatioN/A

Dividend YieldN/A

Beta0.31

Lipocine Inc., a specialty pharmaceutical company, focuses on the development of pharmaceutical products in the area of men's and women's health. Its primary development programs are based on oral delivery solutions for poorly bioavailable drugs. The company has a portfolio of product candidates designed to produce pharmacokinetic characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability. Its lead product candidate is TLANDO, an oral testosterone replacement therapy. The company's pipeline candidates also include LPCN 1111, an oral testosterone therapy product for once daily dosing that completed Phase II testing; LPCN 1107, an oral hydroxyprogesterone caproate product for the prevention of recurrent preterm birth and has completed an end-of-Phase II meeting with the Food and Drug Administration; and LPCN 1144, an oral prodrug of bioidentical testosterone that is in Phase I Clinical trial for the treatment of non-alcoholic steatohepatitis. Lipocine Inc. is headquartered in Salt Lake City, Utah.

Beat the Market (BTM) Rank^™

3.3 Analyst's Opinion

Consensus Rating
Lipocine has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $3.00, Lipocine has a potential upside of 233.3% from its current price of $0.90.
Amount of Analyst Coverage
Lipocine has only been the subject of 1 research reports in the past 90 days.

2.7 Community Rank

Outperform Votes
Lipocine has received 276 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Lipocine has received 227 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Lipocine has received 54.87% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Lipocine and other stocks. Vote “Outperform” if you believe LPCN will outperform the S&P 500 over the long term. Vote “Underperform” if you believe LPCN will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Lipocine does not currently pay a dividend.
Dividend Growth
Lipocine does not have a long track record of dividend growth.

3.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Lipocine insiders have bought more of their company's stock than they have sold. Specifically, they have bought $70,400.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 10.50% of the stock of Lipocine is held by insiders.
Percentage Held by Institutions
Only 7.65% of the stock of Lipocine is held by institutions.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Lipocine are expected to grow in the coming year, from ($0.19) to ($0.16) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Lipocine is -1.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Lipocine is -1.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Lipocine has a P/B Ratio of 3.60. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Overall Beat the Market Rank^™

1.92 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:LPCN

Previous Symbol

CUSIPN/A

CIK1535955

Webwww.lipocine.com

Phone801-994-7383

Debt

Debt-to-Equity Ratio0.72

Current Ratio5.16

Quick Ratio5.16

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$170,000.00

Price / Sales253.48

Cash FlowN/A

Price / Cash FlowN/A

Book Value$0.25 per share

Price / Book3.60

Profitability

EPS (Most Recent Fiscal Year)($0.50)

Net Income$-13,010,000.00

Net MarginsN/A

Return on Equity-206.04%

Return on Assets-80.10%

Miscellaneous

Employees10

Outstanding Shares47,880,000

Market Cap$43.09 million

Next Earnings Date8/5/2020 (Estimated)

OptionableOptionable

Receive LPCN News and Ratings via Email

Sign-up to receive the latest news and ratings for LPCN and its competitors with MarketBeat's FREE daily newsletter.

Lipocine (NASDAQ:LPCN) Frequently Asked Questions

How has Lipocine's stock been impacted by COVID-19 (Coronavirus)?

Lipocine's stock was trading at $0.4511 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, LPCN shares have increased by 99.5% and is now trading at $0.90. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Lipocine?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Lipocine in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Lipocine.

When is Lipocine's next earnings date?

Lipocine is scheduled to release its next quarterly earnings announcement on Wednesday, August 5th 2020. View our earnings forecast for Lipocine.

How were Lipocine's earnings last quarter?

Lipocine Inc (NASDAQ:LPCN) posted its quarterly earnings results on Thursday, May, 7th. The specialty pharmaceutical company reported ($0.14) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.08) by $0.06. View Lipocine's earnings history.

What price target have analysts set for LPCN?

2 Wall Street analysts have issued 1-year target prices for Lipocine's shares. Their forecasts range from $3.00 to $3.00. On average, they expect Lipocine's share price to reach $3.00 in the next year. This suggests a possible upside of 233.3% from the stock's current price. View analysts' price targets for Lipocine.

Has Lipocine been receiving favorable news coverage?

Media coverage about LPCN stock has been trending somewhat positive recently, InfoTrie reports. InfoTrie identifies negative and positive news coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Lipocine earned a news impact score of 2.0 on InfoTrie's scale. They also gave news headlines about the specialty pharmaceutical company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the next several days. View the latest news aboutLipocine.

Who are some of Lipocine's key competitors?

Some companies that are related to Lipocine include Five Prime Therapeutics (FPRX), CELYAD SA/ADR (CYAD), Evolus (EOLS), Mustang Bio (MBIO), Aptinyx (APTX), Minerva Neurosciences (NERV), Tiziana Life Sciences (TLSA), Evofem Biosciences (EVFM), Sol Gel Technologies (SLGL), Galectin Therapeutics (GALT), Cyclerion Therapeutics (CYCN), BIOFRONTERA AG/ADR (BFRA), Cerecor (CERC), Sierra Oncology (SRRA) and Harrow Health (HROW). View all competitors.

What other stocks do shareholders of Lipocine own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Lipocine investors own include Synergy Pharmaceuticals (SGYP), Flexion Therapeutics (FLXN), Novavax (NVAX), SCYNEXIS (SCYX), Actinium Pharmaceuticals (ATNM), Catalyst Pharmaceuticals (CPRX), Heat Biologics (HTBX), Inovio Pharmaceuticals (INO), Progenics Pharmaceuticals (PGNX) and Cara Therapeutics (CARA).

Who are Lipocine's key executives?

Lipocine's management team includes the following people:

Dr. Mahesh V. Patel, Co-Founder, Chairman, Pres & CEO (Age 62)
Mr. Morgan R. Brown, Exec. VP, CFO & Corp. Sec. (Age 51)
Logan Morse, VP of Sales, Marketing & Operations (Age 49)
Nachiappan Chidambaram, VP of Product Devel. (Age 50)
Dr. William I. Higuchi Ph.D., Chief Scientific Consultant (Age 88)

What is Lipocine's stock symbol?

Lipocine trades on the NASDAQ under the ticker symbol "LPCN."

Who are Lipocine's major shareholders?

Lipocine's stock is owned by a number of retail and institutional investors. Top institutional investors include BlackRock Inc. (1.68%) and Mercer Global Advisors Inc. ADV (0.25%). Company insiders that own Lipocine stock include John W Higuchi, Mahesh V Patel and Morgan R Brown. View institutional ownership trends for Lipocine.

Which institutional investors are buying Lipocine stock?

LPCN stock was bought by a variety of institutional investors in the last quarter, including Mercer Global Advisors Inc. ADV, and BlackRock Inc.. Company insiders that have bought Lipocine stock in the last two years include John W Higuchi, and Mahesh V Patel. View insider buying and selling activity for Lipocine.

How do I buy shares of Lipocine?

Shares of LPCN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Lipocine's stock price today?

One share of LPCN stock can currently be purchased for approximately $0.90.

How big of a company is Lipocine?

Lipocine has a market capitalization of $43.09 million and generates $170,000.00 in revenue each year. The specialty pharmaceutical company earns $-13,010,000.00 in net income (profit) each year or ($0.50) on an earnings per share basis. Lipocine employs 10 workers across the globe.

What is Lipocine's official website?

The official website for Lipocine is www.lipocine.com.

How can I contact Lipocine?

Lipocine's mailing address is 675 ARAPEEN DRIVE SUITE 202, SALT LAKE CITY X1, 84108. The specialty pharmaceutical company can be reached via phone at 801-994-7383 or via email at [email protected]

This page was last updated on 6/6/2020 by MarketBeat.com Staff